Dr Carsten Schmitz-Peiffer Related News
Garvan Scientists acknowledged on World Diabetes Day
14 Nov 2010
Garvan diabetes research has been recognised by the Diabetes Australia Research Trust, which announced that several Garvan scientists would be receiving significant research support over the coming two years.
David Pedersen wins Australian Diabetes Society award
07 Sep 2010
Garvan PhD student David Pedersen won the Pincus Taft Junior Investigator Award last week at the Australian Diabetes Society’s annual conference.
New drug a potential treatment for Type 2 diabetes
MEDIA RELEASE:
22 Jul 2010
Garvan scientists, in association with US pharmaceutical company DiaKine Therapeutics, have shown that a drug candidate, Lisofylline, could be useful in treating Type 2 diabetes. Lysofylline, an anti-inflammatory drug, is currently undergoing clinical trials for other diseases.
Solving a critical part of the insulin puzzle
MEDIA RELEASE:
04 Oct 2007
We are now one step closer to improved treatment of Type 2 diabetes following significant findings made by scientists at the Garvan Institute of Medical Research. The team from Garvan's Diabetes Signalling Unit, led by Associate Professor Trevor Biden and Dr Carsten Schmitz-Peiffer, has identified a very important biological target that will enable them to address one of the major underlying causes of diabetes.
